Pharmacyclics Announces American Society of Hematology Investor Teleconference and Annual Meeting of Stockholders

Dec 01, 2010, 17:07 ET from Pharmacyclics

SUNNYVALE, Calif., Dec. 1, 2010 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) provides an overview of the schedule for the upcoming American Society of Hematology (ASH) annual meeting events from December 4 – 7, 2010. The company also announced that it will host a conference call and live audio webcast on Wednesday, December 8, at 4:30 pm ET to discuss its ASH oral and poster presentations on PCI-32765. The 2010 annual meeting of stockholders is planned for December 9, 2010 at 1:30 PM pacific time at the Company's offices, 999 East Arques Avenue, Sunnyvale, CA 94085.

ASH Conference Call and Webcast Details:

Date: Wednesday, December 8, 2010

Time: 4:30 pm ET

Listen via Internet:

Live Participant Dial In (Toll Free): 877-407-8133

Live Participant Dial In (International): 201-689-8040

To access the live audio broadcast or the subsequent archived recording, log on to The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at

American Society of Hematology Events December 4-7, 2010:

Three oral presentations and one poster presentation for Btk Inhibitor, PCI-32765 were accepted at the American Society of Hematology (ASH) National Meeting in Orlando, FL on December 4-7th, 2010. The ASH Presentations relating to our Btk Inhibitor PCI-32765 are scheduled as follows:


Publication Number:  1385

TITLE:  The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals

Presenter: Sarah E.M. Herman, PhD

Date / Time:   Saturday, December 4, 2010 5:30 PM - 7:30 PM

Location:  Orange County Convention Center, Hall A3/A4   Poster Board no.: I-365


Publication Number:  45

TITLE: Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.

Presenter: Sabine Ponader, PhD

Session Date / Time:  Sunday, December 5, 2010 at 5:00 PM

Room:  Orange County Convention Center, Valencia B/C


Publication Number:  57

TITLE:  The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL):An Update on Ongoing Phase 1 Studies

Presenter: Jan Burger, MD, PhD

Session Date / Time:  Sunday, December 5, 2010 at  5:00 PM  

Room:  Orange County Convention Center, Valencia D


Publication Number:  964

TITLE: The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

Presenter: Nathan Fowler, MD

Session Date / Time:  Tuesday, December 7, 2010 at 8:15 AM

Room:  Orange County Convention Center, 312

A Poster Presentation for our HDAC Inhibitor PCI-24781 was accepted at ASH, the details are:


Publication Number: 3914

TITLE: The Histone Deacetylase (HDAC) Inhibitor PCI-24781 Decreases Pro-Inflammatory Cytokine Secretion In Vitro and In Vivo and Protects Against Endotoxemia In a Sepsis Model

Date / Time: Monday, December  6, 2010 at 6:00 PM - 8:00 PM

Location: Orange County Convention Center, Hall A3/A4  Poster Board no.:III-693

2010 Annual Meeting of Stockholders

Date: Thursday, December 9, 2010

Time: 1:30 pm PT

Location: Pharmacyclics offices

                       999 East Arques Ave, Sunnyvale, CA 94085

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.

Presently, Pharmacyclics has four product candidates in clinical development, a clinical development candidate in late stage preclinical evaluation and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at

SOURCE Pharmacyclics